MACROGENICS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
MACROGENICS, INC. (MGNX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2022-02-24
- MACROGENICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-12-31 was $0.00.
- MACROGENICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- MACROGENICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-06-30 was $0.00.
- MACROGENICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- MACROGENICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $0.00.
- MACROGENICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- MACROGENICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $6.41M.
- MACROGENICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2018 was $0.00.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-24 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | $0.00 derived: sum of 3 quarters · filed 2022-02-24 | $0.00 10-K · filed 2022-02-24 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $0.00 derived: sum of 2 quarters · filed 2020-11-04 | $0.00 10-Q · filed 2020-11-04 | $0.00 derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $0.00 10-Q · filed 2020-07-31 | $0.00 derived: sum of 3 quarters · filed 2022-02-24 | $4.42M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-05 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | $4.42M derived: sum of 3 quarters · filed 2022-02-24 | $4.42M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $4.42M derived: sum of 2 quarters · filed 2022-02-24 | $4.42M derived: sum of 3 quarters · filed 2022-02-24 | $6.41M 10-K · filed 2022-02-24 |
| 2019-09-30 | $4.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $4.42M derived: sum of 2 quarters · filed 2020-11-04 | $6.41M 10-Q · filed 2020-11-04 | $6.41M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $1.99M 10-Q · filed 2020-07-31 | $1.99M derived: sum of 3 quarters · filed 2021-02-25 | $1.99M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $1.99M 10-Q · filed 2020-05-05 | $1.99M derived: sum of 2 quarters · filed 2021-02-25 | $1.99M derived: sum of 3 quarters · filed 2021-02-25 | $1.99M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $0.00 derived: sum of 2 quarters · filed 2021-02-25 | $0.00 derived: sum of 3 quarters · filed 2021-02-25 | $0.00 10-K · filed 2021-02-25 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $0.00 derived: sum of 2 quarters · filed 2019-11-06 | $0.00 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $0.00 10-Q · filed 2019-07-31 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-01 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |